Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 3151 to 3200 of 4089 results for patient

  1. Supporting adult carers (QS200)

    This quality standard covers the provision of support for adults aged 18 or over who provide unpaid care for 1 or more people aged 16 or over with health and social care needs. It describes high-quality care in priority areas for improvement.

  2. What is the clinical and cost effectiveness of cognitive behavioural therapy (CBT) for adults with tinnitus delivered by appropriately trained healthcare professionals other than psychologists (for example, audiologists)?

    by psychologists because this is considered important for achieving good patient outcomes. Taking into account the clinical and economic...

  3. What is the clinical and cost effectiveness of psychological therapies for children and young people who have tinnitus-related distress?

    by psychologists because this is considered important for achieving good patient outcomes. Taking into account the clinical and economic...

  4. Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]

    In development Reference number: GID-TA11154 Expected publication date: TBC

  5. PillCam COLON 2 for investigation of the colon through direct visualisation

    In development Reference number: GID-DG10083 Expected publication date: TBC

  6. Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]

    In development Reference number: GID-TA11162 Expected publication date:  28 July 2027

  7. Monofocal intraocular lenses for cataract surgery (provisional title)

    In development Reference number: GID-HTE10090 Expected publication date: TBC

  8. MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor

    In development Reference number: GID-IPG10441 Expected publication date: TBC

  9. MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor: draft scope consultation

    We are listening to your views on this Interventional procedures guidance. Comments close 11 February 2026.

  10. Published

    The complete list of all our published indicators, for measuring outcomes that reflect the quality of care or processes, linked by evidence to improved outcomes.

  11. Vibegron for treating symptoms of overactive bladder syndrome (TA999)

    Evidence-based recommendations on vibegron (Obgemsa) for treating symptoms of overactive bladder syndrome in adults.

  12. Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies (TA1073)

    Evidence-based recommendations on marstacimab (Hympavzi) for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies.

  13. Low back pain and sciatica in over 16s: assessment and management (NG59)

    This guideline covers assessing and managing low back pain and sciatica in people aged 16 and over. It outlines physical, psychological, pharmacological and surgical treatments to help people manage their low back pain and sciatica in their daily life. The guideline aims to improve people’s quality of life by promoting the most effective forms of care for low back pain and sciatica.

  14. Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]

    Discontinued Reference number: GID-TAG507

  15. Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]

    In development Reference number: GID-TA11410 Expected publication date: TBC

  16. Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage small-cell lung cancer [ID6412]

    In development Reference number: GID-TA11497 Expected publication date: TBC

  17. Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]

    Awaiting development Reference number: GID-TA11343 Expected publication date: TBC

  18. Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]

    In development Reference number: GID-TA11336 Expected publication date: TBC

  19. Artificial intelligence software to help detect and characterise colorectal polyps

    In development Reference number: GID-DG10118 Expected publication date: TBC

  20. Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]

    In development Reference number: GID-TA11501 Expected publication date: TBC

  21. Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 11 February 2026.

  22. Artificial intelligence (AI) technologies to help detect prostate cancer on multiparametric (mp) MRI

    In development Reference number: GID-HTE10089 Expected publication date: TBC

  23. Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]

    Awaiting development Reference number: GID-TA11509 Expected publication date: TBC

  24. Ublituximab for treating relapsing multiple sclerosis (TA1025)

    Evidence-based recommendations on ublituximab (Briumvi) for treating relapsing multiple sclerosis in adults.

  25. Acoramidis for treating transthyretin amyloidosis with cardiomyopathy (TA1121)

    Evidence-based recommendations on acoramidis (Beyonttra) for treating wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults.

  26. The PressureWire fractional flow reserve measurement system for coronary artery disease (MIB2)

    NICE has developed a Medtech Innovation Briefing (MIB) on the PressureWire fractional flow reserve measurement system

  27. Therapeutic amnioinfusion for oligohydramnios during pregnancy (excluding labour) (HTG124)

    Evidence-based recommendations on therapeutic amnioinfusion for treating oligohydramnios during pregnancy (excluding labour). This involves injecting a substance similar to amniotic fluid into the space around the baby.

  28. Corneal endothelial transplantation (HTG195)

    Evidence-based recommendations on corneal endothelial transplantation. This involves replacing only the innermost layers of the cornea with a healthy section from a donor eye without disturbing the overall structure.

  29. HIV testing: increasing uptake among people who may have undiagnosed HIV (NG60)

    This guideline covers how to increase the uptake of HIV testing in primary and secondary care, specialist sexual health services and the community. It describes how to plan and deliver services that are tailored to the local prevalence of HIV, promote awareness of HIV testing and increase opportunities to offer testing to people who may have undiagnosed HIV.

  30. Long-acting reversible contraception (CG30)

    This guideline covers long-acting reversible contraception. It aims to increase the use of long-action reversible contraception by improving the information given to women about their contraceptive choices.

  31. Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education (NG213)

    This guideline covers support for disabled children and young people with severe complex needs, from birth to 25 years. It aims to encourage education, health and social care services to work together and provide more coordinated support to children and young people, and their families and carers.

  32. Antenatal care (QS22)

    This quality standard covers the routine antenatal care that women and their babies should receive during pregnancy. It describes high-quality care in priority areas for improvement.

  33. Familial hypercholesterolaemia (QS41)

    This quality standard covers identifying and managing familial hypercholesterolaemia (FH) in children, young people and adults. FH is a type of high cholesterol that runs in families and increases the risk of heart disease. The quality standard describes high-quality care in priority areas for improvement.

  34. Is the use of chlorhexidine body wash associated with increased antimicrobial resistance?

    surgical and infection control teams, and should also take into account patient risk factors, such as whether the person is an S. aureus...

  35. Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]

    In development Reference number: GID-TA11402 Expected publication date: TBC

  36. Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6146]

    Awaiting development Reference number: GID-TA11222 Expected publication date: TBC

  37. Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441]

    In development Reference number: GID-TA11544 Expected publication date:  14 May 2026

  38. Ex-situ machine perfusion devices for extracorporeal preservation of lungs for transplant

    In development Reference number: GID-HTE10084 Expected publication date: TBC

  39. Surgical mesh for ventral hernias

    In development Reference number: GID-HTE10080 Expected publication date: TBC

  40. In-situ normothermic regional perfusion of the abdomen for livers donated after controlled circulatory death

    In development Reference number: GID-IPG10405 Expected publication date:  19 November 2026

  41. MMprofiler for prognostic risk classification in multiple myeloma (MIB270)

    NICE has developed a medtech innovation briefing (MIB) on MMprofiler for prognostic risk classification in multiple myeloma .

  42. NICE and virtual wards

    We're working with colleagues to ensure that virtual wards are used in a way that maximises the value for patients and the NHS.

  43. Facial erythema of rosacea: brimonidine tartrate gel (ESNM43)

    Summary of the evidence on brimonidine tartrate gel for treating facial erythema of rosacea to inform local NHS planning and decision-making

  44. Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion (TA1004)

    Evidence-based recommendations on faricimab (Vabysmo) for treating visual impairment caused by macular oedema after retinal vein occlusion in adults.

  45. Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA1007)

    Evidence-based recommendations on rucaparib (Rubraca) for the maintenance treatment of relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary peritoneal cancer that has completely or partially responded to platinum-based chemotherapy in adults.

  46. Risankizumab for treating moderately to severely active ulcerative colitis (TA998)

    Evidence-based recommendations on risankizumab (Skyrizi) for treating moderately to severely active ulcerative colitis in adults.

  47. Liraglutide for managing overweight and obesity (TA664)

    Evidence-based recommendations on liraglutide (Saxenda) for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults.

  48. Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen (TA1087)

    Evidence-based recommendations on betula verrucosa (Itulazax 12 SQ Bet) for treating moderate to severe allergic rhinitis or conjunctivitis caused by pollen from trees in the birch allergy group in adults.

  49. Technologies to support the rapid diagnosis of endometriosis (provisional title)

    In development Reference number: GID-HTE10082 Expected publication date: TBC